The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global biosimilar market was valued at US$ 13.0 Billion in 2021.
We expect the global biosimilar market to exhibit a CAGR of 26.1% during 2022-2027.
The rising prevalence of various chronic diseases, along with the continuous patent expiry of
numerous blockbuster biologic drugs, is primarily driving the global biosimilar market.
The sudden outbreak of the COVID-19 pandemic had led to the delay in clinical trials for biosimilars
due to the rising focus on the production of effective vaccines against coronavirus infection, thereby
negatively impacting the market for biosimilars.
Based on the molecule, the global biosimilar market has been bifurcated into Infliximab, Insulin
Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, and Follitropin Alfa. Currently,
Infliximab holds the majority of the total market share.
Based on the indication, the global biosimilar market has been divided into auto-immune diseases,
oncology, diabetes, blood disorder, growth deficiency, and female infertility. Among these, auto-
immune diseases currently exhibit a clear dominance in the market.
Based on the manufacturing type, the global biosimilar market has been classified into in-house
manufacturing and contract manufacturing. Currently, in-house manufacturing accounts for the
largest market share.
On a regional level, the market has been classified into the United States, Germany, France, Italy,
Spain, United Kingdom, Japan, India, South Korea, and others, where Italy currently dominates the
Some of the major players in the global biosimilar market include Novartis, Pfizer, Teva, Celltrion,
Merck & Co, Samsung Bioepis, Eli Lilly, Biocon, Dr. Reddy's Laboratories, Amgen, Boehringer
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at